M&A Deal Summary

Boehringer Ingelheim Acquires Abexxa Biologics

On September 21, 2021, Boehringer Ingelheim acquired life science company Abexxa Biologics

Acquisition Highlights
  • This is Boehringer Ingelheim’s 8th transaction in the Life Science sector.
  • This is Boehringer Ingelheim’s 2nd transaction in the United States.
  • This is Boehringer Ingelheim’s 1st transaction in Texas.

M&A Deal Summary
Date 2021-09-21
Target Abexxa Biologics
Sector Life Science
Buyer(s) Boehringer Ingelheim
Deal Type Add-on Acquisition

Target

Abexxa Biologics

Arlington, Texas, United States
website
Abexxa Biologics is a biopharmaceutical company taking an approach in the fields of immuno-oncology and oncology to develop the next generation of precision medicine. Abexxa is focused on developing novel therapeutics around its newly discovered class of intracellular antigens (atypical HLA-peptide complexes) on cancerous cells. Abexxa Biologics is based in Arlington, Texas.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Boehringer Ingelheim

Ingelheim am Rhein, Germany

website

Category Company
Sector Healthcare Services
DESCRIPTION

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies.

DEAL STATS #
Overall 10 of 13
Sector (Life Science) 8 of 11
Type (Add-on Acquisition) 9 of 11
State (Texas) 1 of 1
Country (United States) 2 of 4
Year (2021) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-10 NBE-Therapeutics AG

Basel, Switzerland

NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody-drug conjugate (iADC) products. NBE-Therapeutics advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb Display technology for antibody discovery, its SMAC-Technology for site-specific payload conjugation of toxins to antibodies, and a novel highly effective and immune-stimulatory anthracycline-based toxin platform.

Buy €1.2B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-11 Boehringer Ingelheim s Benefit-Risk Analytic System

Ingelheim am Rhein, Germany

Boehringer Ingelheim's Benefit-Risk Analytic System (BRASS) is a software solution designed to support causal analysis of drug safety data in a highly regulated environment.

Sell -
Mergr

Product

Company

Legal